Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification
Open Access
- 23 June 2017
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (9), 3368-3374
- https://doi.org/10.1210/jc.2017-00773
Abstract
Background Most pituitary neuroendocrine tumors (PitNETs) show benign behavior, but a substantial number are invasive, recur, or resist medical treatment. Based on a retrospective case-control study, we recently proposed a classification of PitNETs of prognostic relevance. This prospective study aims to test the value of this classification in an independent patient cohort. Methods All patients who underwent PitNET surgery from 2007 to 2012 in one single center were included. Using a grading system based on invasion on magnetic resonance imaging, immunocytochemical profile, Ki-67, mitotic index, and p53 positivity, tumors were classified. Progression-free survival of the graded tumors was calculated by the Kaplan-Meier method and compared using the log-rank test. A multivariate analysis, using a Cox regression model, was also performed. Results In total, 365 patients had grade 1a PitNETs (51.2%), followed by grade 2a (32.3%), 2b (8.8%), and 1b tumors (7.7%). Of 213 patients with a follow-up, 42% had recurrent (n = 52) or progressive disease (n = 37) at 3.5 years. Grade was a significant predictor of progression-free survival (P < 0.001). Multivariate analysis indicated grade (P < 0.001), age (P = 0.035), and tumor type (P = 0.028) as independent predictors of recurrence and/progression. This risk was 3.72-fold higher for a grade 2b tumor compared with grade 1a tumor. Conclusions Our data suggest that classification of PitNETs into five grades is of prognostic value to predict postoperative tumor behavior and identifies patients who have a high risk of early recurrence or progression. It therefore will allow clinicians to adapt their therapeutic strategies and stratify patients in future clinical trials.Keywords
This publication has 26 references indexed in Scilit:
- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposalEndocrine-Related Cancer, 2017
- Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patientsNeurosurgical Review, 2016
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012Neuro-Oncology, 2015
- Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modificationsActa Neuropathologica Communications, 2015
- Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and PrognosisNeuroendocrinology, 2015
- Aggressive pituitary adenomas—diagnosis and emerging treatmentsNature Reviews Endocrinology, 2014
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatmentClinical Endocrinology, 2012
- Atypical pituitary adenomas: incidence, clinical characteristics, and implicationsJournal of Neurosurgery, 2011
- Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor RegistryActa Endocrinologica, 2007
- The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgeryJournal of Neurosurgery, 2002